Research on Contract Dispute Resolution of Chinese Frozen Embryo Companies
Wonkwang University Legal Research Institute · 30.06.2025 · 33 · 61-94
DOI: 10.22397/bml.2025.33.61 ↗Kurz gefasst
Fachartikel in der Zeitschrift Wonkwang University Legal Research Institute, online erschienen am 30.06.2025. Verfasst von Fanqi Sun und 1 weiteren Autor:innen.
Abstract (Originalsprache)
With the development of modern medical technology, frozen embryo technology is widely used in the field of artificial assisted reproduction, giving birth to many frozen embryo companies. By the end of 2024, China has established 600 artificial assisted reproductive technology companies, with a capital scale of more than 50 billion yuan. However, its business expansion has brought about a series of contract disposition issues, legal disputes, and ethical controversies, which urgently require in-depth research on regulatory paths from the legislative and judicial levels. From a medical perspective, frozen embryo technology is the process of storing in vitro fertilized embryos at ultra-low temperatures. The principle is based on cellular and low-temperature biology, and the operation includes fertilization, culture, freezing, and thawing. There are slow and vitrification freezing methods, the latter of which is widely used. At the legal level, although there is no unified definition, the relevant provisions of the Civil Code and judicial practice regulate it from the perspectives of personality rights, property rights, and contracts. In the past five years, China has made significant progress in the application, scientific research, and policy regulations of this technology. The frozen embryo industry has characteristics of technicality, risk, and service diversity. The technicality is reflected in the professional requirements for extraction, preservation, and confidentiality; Risk includes genetic material, moral and legal risks; The services cover preservation, cultivation, genetic analysis, and transplantation. There are various types of contracts for frozen embryo companies, such as trading, storage, and service contracts, and there are many issues in signing and fulfilling them. The contract involves rights, obligations, and terms, including services, terms, fees, responsibilities, etc. The breach of contract includes improper storage, failure to meet service standards, unreasonable changes in fees, etc. The legal consequences include compensation for losses, restoration to the original state, revocation of business qualifications, etc. The dispute resolution methods include litigation, arbitration, mediation, and specialized agency management, while the relief methods include compensation for damages and the realization of rights based on judgment. In terms of contract disposal and improvement, 1) transfer is strictly restricted by laws and ethics, 2) while donation has clear rules and management mechanisms, 3) requiring standardized procedures and subjects. In the future, it is necessary to expand research on legal issues related to frozen embryos from the aspects of technology, legal system, ethics, etc. 随着现代医学技术的发展,冷冻胚胎技术在人工辅助生殖领域应用广泛,催生了众多冷冻胚胎公司。截至2024年底,中国已经成立了600家人工辅助生殖技术公司,资本规模突破500亿元。然而,其业务拓展带来了一系列合同处分问题及法律纠纷与伦理争议,亟待从立法和司法层面深入研究规范路径。从医学角度看,冷冻胚胎技术是将体外受精胚胎置于超低温保存,原理基于细胞和低温生物学,操作包括受精、培养、冷冻和解冻等环节,有慢速和玻璃化冷冻法,后者应用广。法律层面,虽无统一定义,但《民法典》相关规定及司法实践从人格权、物权、合同角度对其进行规制。近五年我国该技术在应用、科研、政策法规方面均有显著进展。冷冻胚胎行业具有技术性、风险性和服务多样性特征。技术性体现在提取、保存和保密的专业要求;风险性包括遗传物质、道德和法律风险;服务涵盖保存、培养、遗传分析和移植等。冷冻胚胎公司合同有交易、保管、服务合同等种类,存在签订和履行中的诸多问题。合同内容涉及权利义
Zitieren
APA
Sun, F., & Kim, J. (2025). Research on Contract Dispute Resolution of Chinese Frozen Embryo Companies. Wonkwang University Legal Research Institute, 33, 61-94. https://doi.org/10.22397/bml.2025.33.61
Vancouver
Sun F, Kim J. Research on Contract Dispute Resolution of Chinese Frozen Embryo Companies. Wonkwang University Legal Research Institute. 2025;33:61-94. doi:10.22397/bml.2025.33.61
BibTeX
@article{Sun2025,
author = {Sun, Fanqi and Kim, Jungjin},
title = {Research on Contract Dispute Resolution of Chinese Frozen Embryo Companies},
journal = {Wonkwang University Legal Research Institute},
year = {2025},
volume = {33},
pages = {61--94},
doi = {10.22397/bml.2025.33.61}
}
EUVIMED